Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
US · Macroeconomic Factors/Risks · Forecasts
Macro
US · Macroeconomic Factors/Risks · ForecastsDenali Therapeutics Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)
United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Likelihood Legend A++ is best, F- worst
- A++
- A+
- A
-
Very Unlikely - B+
- B
-
Unlikely
- C+
- C
- D+
- D
- D-
-
Avg.
- E+
- E-
-
Unlikely - F+
- F
- F-
-
Very Unlikely
Indicator
All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.
Rating